Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 3

A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

Key facts

Where
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei, Huzhou, Jiangmen, Nanchang, Nanjing, Nantong, Ningbo, Pingxiang, Qingdao, Quanzhou, Shanghai, Shenzhen, Suzhou, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xuzhou, Yangzhou, and Yixing, ChinaSee the 48 sites
Phase
Phase 3

Where in China

  • Beijing Children's Hospital, Capital Medical UniversityBeijing, ChinaContact: Boehringer IngelheimNo longer taking part
  • China-Japan Friendship HospitalBeijing, ChinaContact: Boehringer IngelheimNo longer taking part
  • Peking Union Medical College HospitalBeijing, ChinaContact: Boehringer IngelheimNo longer taking part
  • Peking University Third HospitalBeijing, ChinaContact: Boehringer IngelheimNo longer taking part
  • The First Hospital of Jilin UniversityChangchun, ChinaContact: Boehringer IngelheimNo longer taking part
  • The Second Hospital of Jilin UniversityChangchun, ChinaContact: Boehringer IngelheimNo longer taking part
  • The Second Xiangya Hospital of Central South UniversityChangsha, ChinaContact: Boehringer IngelheimNo longer taking part
  • West China Hospital，Sichuan UniversityChengdu, ChinaContact: Boehringer IngelheimNo longer taking part
  • First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, ChinaContact: Boehringer IngelheimNo longer taking part
  • Guangdong Provincial People's HospitalGuangzhou, ChinaContact: Boehringer IngelheimNo longer taking part
  • Guizhou Provincial People's HospitalGuiyang, ChinaContact: Boehringer IngelheimNo longer taking part
  • Hangzhou First People's HospitalHangzhou, ChinaContact: Boehringer IngelheimNo longer taking part
  • Sir Run Run Shaw Hospital Zhejiang University School of MedicineHangzhou, ChinaContact: Boehringer IngelheimNo longer taking part
  • The Second Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaContact: Boehringer IngelheimNo longer taking part
  • Zhejiang HospitalHangzhou, ChinaContact: Boehringer IngelheimNo longer taking part
  • The First Affiliated Hospital of Anhui Medical UniversityHefei, ChinaContact: Boehringer IngelheimNo longer taking part
  • Huzhou Central HospitalHuzhou, ChinaContact: Boehringer IngelheimNo longer taking part
  • Jiangmen Central HospitalJiangmen, ChinaContact: Boehringer IngelheimNo longer taking part
  • The First Affiliated Hospital of NanChang UniversityNanchang, ChinaContact: Boehringer IngelheimNo longer taking part
  • The Second Affiliated Hospital to Nanchang UniversityNanchang, ChinaContact: Boehringer IngelheimNo longer taking part
  • Nanjing Drum Tower hospitalNanjing, ChinaContact: Boehringer IngelheimNo longer taking part
  • Nanjing First HospitalNanjing, ChinaContact: Boehringer IngelheimNo longer taking part
  • Affiliated Hospital of Nantong UniversityNantong, ChinaContact: Boehringer IngelheimNo longer taking part
  • Ningbo Medical Center Lihuili HospitalNingbo, ChinaContact: Boehringer IngelheimNo longer taking part
  • The First Affiliated Hospital of Ningbo UniversityNingbo, ChinaContact: Boehringer IngelheimNo longer taking part
  • Pingxiang People's HospitalPingxiang, ChinaContact: Boehringer IngelheimNo longer taking part
  • QingDao Municipal HospitalQingdao, ChinaContact: Boehringer IngelheimNo longer taking part
  • The Second Affiliated Hospital of Fujian Medical UniversityQuanzhou, ChinaContact: Boehringer IngelheimNo longer taking part
  • Huadong Hospital Affiliated to Fudan UniversityShanghai, ChinaContact: Boehringer IngelheimNo longer taking part
  • Qingpu Branch of Zhongshan Hospital Affiliated to Fudan UniversityShanghai, ChinaContact: Boehringer IngelheimNo longer taking part
  • Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaContact: Boehringer IngelheimNo longer taking part
  • Shanghai Fifth People's Hospital Affiliated to Fudan UniversityShanghai, ChinaContact: Boehringer IngelheimNo longer taking part
  • Shanghai General HospitalShanghai, ChinaContact: Boehringer IngelheimNo longer taking part
  • Shanghai Pulmonary HospitalShanghai, ChinaContact: Boehringer IngelheimNo longer taking part
  • The Children's Hospital of Fudan UniversityShanghai, ChinaContact: Boehringer IngelheimNo longer taking part
  • Tongji Hospital Tongji UniversityShanghai, ChinaContact: Boehringer IngelheimNo longer taking part
  • Zhongshan Hospital Affiliated to Fudan UniversityShanghai, ChinaContact: Boehringer IngelheimNo longer taking part
  • Shenzhen People's HospitalShenzhen, ChinaContact: Boehringer IngelheimNo longer taking part
  • The First Affiliated Hospital of Soochow UniversitySuzhou, ChinaContact: Boehringer IngelheimNo longer taking part
  • Tianjin Medical University General HospitalTianjin, ChinaContact: Boehringer IngelheimNo longer taking part
  • The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaContact: Boehringer IngelheimNo longer taking part
  • Wenzhou People's HospitalWenzhou, ChinaContact: Boehringer IngelheimNo longer taking part
  • Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaContact: Boehringer IngelheimNo longer taking part
  • Wuxi People's HospitalWuxi, ChinaContact: Boehringer IngelheimNo longer taking part
  • First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, ChinaContact: Boehringer IngelheimNo longer taking part
  • The Affiliated Hospital of Xuzhou Medical CollegeXuzhou, ChinaContact: Boehringer IngelheimNo longer taking part
  • Northern Jiangsu People's HospitalYangzhou, ChinaContact: Boehringer IngelheimNo longer taking part
  • Yixing People's HospitalYixing, ChinaContact: Boehringer IngelheimNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Boehringer Ingelheim
Trial code
NCT07915219EU 2026-527086-30-00
Record updated
12 November 2026
Original description
This study is for adults and adolescents who are at least 12 years old and have bronchiectasis. People can participate if they completed a previous study with the study medicine called verducatib. The purpose of this study is to find out how well verducatib is tolerated when people with bronchiectasis take it for a long time. The study also looks at breathing problems, how often lung flare-ups happen, and how quickly lung function changes.Read full original descriptionShow less

An Open-label, Roll-over Study Evaluating the Long-term Safety and Efficacy of an Oral Dose of Verducatib q.d. in Patients With Bronchiectasis (AIRTIVITY®-ON)

This study is for adults and adolescents who are at least 12 years old and have bronchiectasis. People can participate if they completed a previous study with the study medicine called verducatib. The purpose of this study is to find out how well verducatib is tolerated when people with bronchiectasis take it for a long time. The study also looks at breathing problems, how often lung flare-ups happen, and how quickly lung function changes.

This is a roll-over study for participants who completed a previous study with verducatib: AIRTIVITY® (1397-0014) or CLAIRLEAF® (1397-0017). All participants receive verducatib. Participants take verducatib as tablets once a day at home. They may continue their usual treatment for bronchiectasis during the study.

Participants can stay in the study for up to 1 year and 9 months. Treatment with verducatib can continue for up to 1 year and 6 months. About 6 study visits are done at the study site and about 4 are done by phone. At all visits, the doctors check participants' health and collect information on any health problems that occur during the study. The doctors also look at lung flare-ups and measure lung function over time.

Inclusion: Participants (adults and adolescents ≥12 years of age) who completed the treatment period in trials 1397-0014 or 1397-0017 as planned per protocol and did not discontinue trial treatment prematurely; Male or female participants. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per International Council of Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the participant information; Signed and dated written informed consent and assent, if applicable, prior to admission to the trial, in accordance with Good Clinical Practice (GCP) and local legislation.

Exclusion: Participants who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial; Moderate or severe liver disease (defined by Child-Pugh score B or C hepatic impairment), unless the investigator determines it is in the best interest of the participant to enrol in the trial; Any relevant pulmonary, gastrointestinal, hepatic, renal, cardiovascular, metabolic, immunological, hormonal, or other disorder that, in the opinion of the investigator, may put the participant at risk by participating in the study; Participants not expected to comply with the protocol requirements or not expected to complete the trial as scheduled, i.e. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the participant an unreliable trial participant; Further exclusion criteria apply; Estimated glomerular filtration rate (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (adults) and Chronic Kidney Disease Under 25 (CKiD-U25) (adolescents) <30 mL/min at Visit 1 (or at the last safety assessment in the parent trial, if no more than 6 weeks passed since then), unless the investigator determines it is in the best interest of the participant to enrol in the trial; An absolute blood neutrophil count <1000/mm\^3 (equivalent to <1000 cells/µL or <10\^9 cells/L) at Visit 1 (or at the last safety assessment in the parent trial, if no more than 6 weeks passed since then); Any findings in the medical examination and/or laboratory value assessed at Visit 1 (or at the last safety assessment in the parent trial, concerning the laboratory tests, if no more than 6 weeks passed since then), that in the opinion of the investigator may put the participant at risk by participating in the trial; Diagnosis of primary or secondary immunodeficiency made after end of treatment in preceding trial.

ClinicalTrials.gov NCT07915219 · EU CTIS 2026-527086-30-00